Baxter International Inc. said it has expanded a deal with Japan’s largest drug maker to bring its cell-based vaccine technology to that country.
The Deerfield-based medical product giant said terms of the agreement with Osaka, Japan-based Takeda Pharmaceutical Company Limited call for “Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.” Get the full story »
